← All Signals

🏥 FDA: Wizcure Pharmaa Private Limited — Class II

healthcarebearishSource: FDA
95%Confidence
0Views
FDASource
2026-03-16Date

Summary

FDA recall for Wizcure Pharmaa's ophthalmic strips due to sterility and cGMP issues indicates significant quality control failures at the manufacturer Omni Lens. This poses regulatory and reputational risks for distributor HUB Pharmaceuticals and may impact supply of diagnostic eye care products.

Actionable: Monitor HUB Pharmaceuticals for potential supply disruptions and regulatory scrutiny.

AI Confidence: 95%

Data Points

firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productBioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT. Ltd., 5 - Samrudhhi, Opp. Sakar-III, Navrangpur

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now